TMEFF1 and benign neoplasm: The positive and high expression rates of TMEFF1 in ovarian cancer were 89.0% (81/91) and 63.7% (58/91), respectively, which were significantly higher than those in borderline tumors, 58.3% (7/12) and 33.3% (4/12) (P = 0.014, 0.06), benign tumors, 38.5% (5/13) and 15.4% (2/13) (P < 0.001, 0.002), and normal ovarian epithelial tissue, 28.6% (4/14), and 7.1% (1/14) (P < 0.001, 0.001; Fig. 6A; Table 3).